AsthmaNCT06026202

Non-Eosinophilic Biological Effects of IL-5

An observational study of Asthma, run by Imperial College London at 1 site in United Kingdom.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Trial summary

This study aims to investigate the role of IL-5 in suppressing anti-viral immune responses in bronchial epithelial cells (BECs) and in peripheral blood mononuclear cells (PBMCs) from 5 people with asthma. Read more about this study

Who is it for?: Ages 18 years and older
Conditions the study is for: Asthma
How many people: 8 participants
Where: 1 siteUnited Kingdom
Study dates: 1 Sep 2023to 22 Dec 2025
Phase: Observational
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 years and older
All sexes
No healthy volunteers
Adult, Older adult

Study population: Those with mild asthma on as required salbutamol only.

Must be eligible for the study 'Mechanisms of Adverse Effects of Long-Acting Beta-Agonists in Asthma' (MAELABA) (19SM5101).

Trial locations and contacts

1 site in 1 country.

United Kingdom1 site

Imperial College London
London, London, W2 1NY

Other trials in United Kingdom

About this study

Official title: Non-Eosinophilic Biological Effects of Interleukin 5 (IL-5) - Role of IL-5 in Suppressing Anti-Viral Immunity in Bronchial Epithelial Cells and Dendritic Cells in Asthma

Read the detailed description

IL-5 has been shown to be present in higher levels in those with asthma, more so during viral infection. The investigators know from existing evidence that having increased levels of interferon (IFN) reduces asthma exacerbations and viral load. The investigators suspect that IL-5 reduces the immune response during viral infection in bronchial epithelial cells (BECs) and peripheral blood mononuclear cells (PBMCs) by reducing levels of IFN. The aim is to investigate if increased IL-5 in stable eosinophilic asthma and asthma exacerbations suppresses anti-viral immunity in bronchial epithelial cells and in peripheral blood mononuclear cells directly via IL-5 receptor signalling, suppressing rhinovirus induction of IFNs. The investigators also will evaluate if anti-IL-5 therapies suppress IL-5 concentrations in stable and exacerbated asthma in vivo and whether suppression of IL-5 in vivo restores deficient anti-viral immunity in BECs and PBMCs, thereby protecting against asthma exacerbations.

Conditions: Asthma
Keywords: Interleukin 5, Bronchial epithelial cells, Peripheral blood mononuclear cells, Peripheral dendritic cells, Interferon, Rhinovirus
Medical subject headings: Asthma

What is being measured

The primary outcome is the main question the study is designed to answer.

IFNB1 Expression in PBMCs Following IL-5 Treatment and RV-A16 Infection (MOI 1)
Peripheral blood mononuclear cells (PBMCs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. IFNB1 mRNA expression was measured by quantitative PCR 8 hours after infection.
Measured: 8 hours post infection
IFNB1 Expression in Bronchial Epithelial Cells (BECs) Infected With RV-A16 (MOI 1) Following IL-5 Treatment
Bronchial epithelial cells (BECs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. IFNB1 mRNA expression was measured by quantitative PCR 8 hours after infection.
Measured: 8 hours post infection

Secondary outcomes (8)

IFN-β Protein Production in PBMCs Infected With RV-A16 (MOI 1) Following IL-5 Treatment
Peripheral blood mononuclear cells (PBMCs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. IFN-β protein levels were measured in cell culture supernatants 24 hours after infection.
Measured: 24 hours after RV-A16 infection
IFN-β Protein Production in BECs Infected With RV-A16 (MOI 1) Following IL-5 Treatment
Bronchial epithelial cells (BECs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. IFN-β protein levels were measured in cell culture supernatants 24 hours after infection.
Measured: 24 hours after RV-A16 infection
IL5RA Expression in PBMCs Infected With RV-A16 (MOI 1) Following IL-5 Treatment
Peripheral blood mononuclear cells (PBMCs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. IL5RA mRNA expression was measured by quantitative PCR 8 hours after infection.
Measured: 8 hours after RV-A16 infection
IL5RA Expression in BECs Infected With RV-A16 (MOI 1) Following IL-5 Treatment
Bronchial epithelial cells (BECs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. IL5RA mRNA expression was measured by quantitative PCR 8 hours after infection.
Measured: 8 hours after RV-A16 infection
CSF2RB Expression in PBMCs Infected With RV-A16 (MOI 1) Following IL-5 Treatment
Peripheral blood mononuclear cells (PBMCs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. CSF2RB mRNA expression was measured by quantitative PCR 8 hours after infection.
Measured: 8 hours after RV-A16 infection
CSF2RB Expression in BECs Infected With RV-A16 (MOI 1) Following IL-5 Treatment
Bronchial epithelial cells (BECs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. CSF2RB mRNA expression was measured by quantitative PCR 8 hours after infection.
Measured: 8 hours after RV-A16 infection
RV-A16 Viral RNA Levels in PBMCs Infected With RV-A16 (MOI 1) Following IL-5 Treatment
Peripheral blood mononuclear cells (PBMCs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. RV-A16 viral RNA levels were quantified by quantitative PCR 8 hours after infection.
Measured: 8 hours after RV-A16 infection
RV-A16 Viral RNA Levels in BECs Infected With RV-A16 (MOI 1) Following IL-5 Treatment
Bronchial epithelial cells (BECs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. RV-A16 viral RNA levels were quantified by quantitative PCR 8 hours after infection.
Measured: 8 hours after RV-A16 infection

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

1 Sep 202322 Dec 2025

First posted7 Sep 2023
Study start1 Sep 2023
Primary completion22 Dec 2025
Study completion22 Dec 2025

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Other trials for AsthmaStudies of the same condition, open and under way.
More trials run by Imperial College LondonThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Observational
Observational model: Other
Time perspective: Prospective
Enrolment: 8 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT06026202
Sponsor's protocol ID: 326910
Status last verified: Nov 2026
First submitted: 25 Aug 2023
Last updated: 6 Nov 2026
Results posted: Yes, on ClinicalTrials.gov
Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

RecruitingPhase 1
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
Asthma
RecruitingPhase 1
A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive
Asthma, Mild Asthma
RecruitingPhase 3
A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma
Asthma Control
Active, not recruitingPhase 2/3
Local Antibiotic Delivery for Community Acquired Pneumonia
Community Acquired Pneumonia (CAP)
RecruitingPhase 2
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
Asthma

All Asthma trials

Study at a glance

From the registry record, last updated by the sponsor on 6 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Non-Eosinophilic Biological Effects of Interleukin 5 (IL-5) - Role of IL-5 in Suppressing Anti-Viral Immunity in Bronchial Epithelial Cells and Dendritic Cells in Asthma
ClinicalTrials.gov ID: NCT06026202
Acronym / sponsor ID: 326910
Conditions: Asthma
Keywords: Interleukin 5, Bronchial epithelial cells, Peripheral blood mononuclear cells, Peripheral dendritic cells, Interferon, Rhinovirus
Study type: Observational
Recruitment status: Completed
Enrolment: 8 participants (actual)
Lead sponsor: Imperial College LondonUniversity, hospital or other
Study start: 1 Sep 2023 (actual)
Primary completion: 22 Dec 2025 (actual)
Study completion: 22 Dec 2025 (actual)
First posted: 7 Sep 2023 (actual)
Results: Posted 6 Nov 2026

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Detailed description

Study design

Observational model: Other
Time perspective: Prospective

Who may qualify

Ages: 18 years and older
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult
Study population: Those with mild asthma on as required salbutamol only.

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Primary outcome

IFNB1 Expression in PBMCs Following IL-5 Treatment and RV-A16 Infection (MOI 1)
Time frame: 8 hours post infection
Peripheral blood mononuclear cells (PBMCs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. IFNB1 mRNA expression was measured by quantitative PCR 8 hours after infection.
IFNB1 Expression in Bronchial Epithelial Cells (BECs) Infected With RV-A16 (MOI 1) Following IL-5 Treatment
Time frame: 8 hours post infection
Bronchial epithelial cells (BECs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. IFNB1 mRNA expression was measured by quantitative PCR 8 hours after infection.

8 secondary outcomes

IFN-β Protein Production in PBMCs Infected With RV-A16 (MOI 1) Following IL-5 Treatment
Time frame: 24 hours after RV-A16 infection
IFN-β Protein Production in BECs Infected With RV-A16 (MOI 1) Following IL-5 Treatment
Time frame: 24 hours after RV-A16 infection
IL5RA Expression in PBMCs Infected With RV-A16 (MOI 1) Following IL-5 Treatment
Time frame: 8 hours after RV-A16 infection
IL5RA Expression in BECs Infected With RV-A16 (MOI 1) Following IL-5 Treatment
Time frame: 8 hours after RV-A16 infection
CSF2RB Expression in PBMCs Infected With RV-A16 (MOI 1) Following IL-5 Treatment
Time frame: 8 hours after RV-A16 infection
CSF2RB Expression in BECs Infected With RV-A16 (MOI 1) Following IL-5 Treatment
Time frame: 8 hours after RV-A16 infection
RV-A16 Viral RNA Levels in PBMCs Infected With RV-A16 (MOI 1) Following IL-5 Treatment
Time frame: 8 hours after RV-A16 infection
RV-A16 Viral RNA Levels in BECs Infected With RV-A16 (MOI 1) Following IL-5 Treatment
Time frame: 8 hours after RV-A16 infection

Results and safety

Results posted to the registry on 6 Nov 2026, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
Asthma Participants	8	8

Primary outcome: IFNB1 Expression in PBMCs Following IL-5 Treatment and RV-A16 Infection (MOI 1)

Time frame: 8 hours post infection. Mean (Standard Deviation). Unit: copies/µL cDNA

Measure	Asthma Participants n = 6
IL-5 0 ng/mL	1808 (3384)
IL-5 10 ng/mL	1333 (2329)
IL-5 50 ng/mL	1206 (2309)
IL-5 100 ng/mL	1396 (2599)

Population analysed: Not all participants contributed samples for all cell types. PBMC data were available from 6 participants and BEC data were available from 5 participants due to sample availability and successful cell culture establishment.

Primary outcome: IFNB1 Expression in Bronchial Epithelial Cells (BECs) Infected With RV-A16 (MOI 1) Following IL-5 Treatment

Time frame: 8 hours post infection. Mean (Standard Deviation). Unit: copies/µL cDNA

Measure	Asthma Participants n = 5
IL-5 0 ng/mL	40.35 (46.69)
IL-5 10 ng/mL	67.14 (115.1)
IL-5 50 ng/mL	115.3 (215.5)
IL-5 100 ng/mL	93.84 (117.2)

8 secondary outcomes are reported in the full results.

Adverse events

Time frame: Adverse events were monitored during bronchoscopy and the immediate post-procedure recovery period, until participants had returned to their normal level of consciousness, had stable vital signs, and were able to swallow, in accordance with hospital guidelines. This usually took around 2 hours. Follow-up assessments were also conducted 1 week after bronchoscopy.. Other adverse events reported at 0% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
Asthma Participants	0 of 8 (0%)	0 of 8 (0%)	0 of 8

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 6 Nov 2026.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.

Related trials for Asthma

RecruitingPhase 1
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
Asthma
RecruitingPhase 1
A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive
Asthma, Mild Asthma
RecruitingPhase 3
A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma
Asthma Control
Active, not recruitingPhase 2/3
Local Antibiotic Delivery for Community Acquired Pneumonia
Community Acquired Pneumonia (CAP)
RecruitingPhase 2
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
Asthma

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

The record lists no contact. Use the official record to reach the sponsor.

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

An observational study of Asthma, run by Imperial College London at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 6 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 6 Nov 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

IFNB1 Expression in PBMCs Following IL-5 Treatment and RV-A16 Infection (MOI 1) (time frame: 8 hours post infection). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06026202.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2026.